Dr. Ian Gallaher
Claim this profileSaint James Community Hospital and Cancer Treatment Center
Studies Prostate Cancer
Studies Small Cell Lung Cancer
5 reported clinical trials
18 drugs studied
Area of expertise
1Prostate Cancer
2Small Cell Lung Cancer
Stage I
Stage II
Stage IV
Affiliated Hospitals
Clinical Trials Ian Gallaher is currently running
Hormone Therapy + Radiation
for Prostate Cancer
This phase III trial uses the Decipher risk score to guide therapy selection. Decipher score is based on the activity of 22 genes in prostate tumor and may predict how likely it is for recurrent prostate cancer to spread (metastasize) to other parts of the body. Decipher score in this study is used for patient selection and the two variations of treatment to be studied: intensification for higher Decipher score or de-intensification for low Decipher score. Patients with higher Decipher risk score will be assigned to the part of the study that compares the use of 6 months of the usual treatment (hormone therapy and radiation treatment) to the use of darolutamide plus the usual treatment (intensification). The purpose of this section of the study is to determine whether the additional drug can reduce the chance of cancer coming back and spreading in patients with higher Decipher score. The addition of darolutamide to the usual treatment may better control the cancer and prevent it from spreading. Alternatively, patients with low Decipher risk score will be assigned to the part of the study that compares the use of radiation treatment alone (de-intensification) to the usual approach (6 months of hormone therapy plus radiation). The purpose of this part of the study is to determine if radiation treatment alone is as effective compared to the usual treatment without affecting the chance of tumor coming back in patients with low Decipher score prostate cancer. Radiation therapy uses high energy to kill tumor cells and reduce the tumor size. Hormone therapy drugs such as darolutamide suppress or block the production or action of male hormones that play role in prostate cancer development. Effect of radiation treatment alone in patients with low Decipher score prostate cancer could be the same as the usual approach in stabilizing prostate cancer and preventing it from spreading, while avoiding the side effects associated with hormonal therapy.
Recruiting2 awards Phase 31 criteria
MRI Monitoring vs. Preventive Brain Radiation
for Small Cell Lung Cancer
This phase III trial studies magnetic resonance imaging (MRI) surveillance and prophylactic cranial irradiation (PCI) to see how well they work compared to MRI surveillance alone in treating patients with small cell lung cancer. MRI scans are used to monitor the possible spread of the cancer with an MRI machine over time. PCI is radiation therapy that is delivered to the brain in hopes of preventing spread of cancer into the brain. The use of brain MRI alone may reduce side effects of receiving PCI and prolong patients' lifespan. Monitoring with MRI scans alone (delaying radiation until the actual spread of the cancer) may be at least as good as the combination of PCI with MRI scans.
Recruiting2 awards Phase 322 criteria
More about Ian Gallaher
Clinical Trial Related7 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Ian Gallaher has experience with
- Intensity-Modulated Radiation Therapy (IMRT)
- Stereotactic Body Radiation Therapy (SBRT)
- Magnetic Resonance Imaging
- Prophylactic Cranial Irradiation
- Bicalutamide
- Buserelin
Breakdown of trials Ian Gallaher has run
Prostate Cancer
Small Cell Lung Cancer
Prostate Adenocarcinoma
Skin Cancer
Merkel Cell Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Ian Gallaher specialize in?
Ian Gallaher focuses on Prostate Cancer and Small Cell Lung Cancer. In particular, much of their work with Prostate Cancer has involved treating patients, or patients who are undergoing treatment.
Is Ian Gallaher currently recruiting for clinical trials?
Yes, Ian Gallaher is currently recruiting for 2 clinical trials in Butte Montana. If you're interested in participating, you should apply.
Are there any treatments that Ian Gallaher has studied deeply?
Yes, Ian Gallaher has studied treatments such as Intensity-Modulated Radiation Therapy (IMRT), Stereotactic Body Radiation Therapy (SBRT), Magnetic Resonance Imaging.
What is the best way to schedule an appointment with Ian Gallaher?
Apply for one of the trials that Ian Gallaher is conducting.
What is the office address of Ian Gallaher?
The office of Ian Gallaher is located at: Saint James Community Hospital and Cancer Treatment Center, Butte, Montana 59701 United States. This is the address for their practice at the Saint James Community Hospital and Cancer Treatment Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.